Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI (CONDI2)
Myocardial Reperfusion Injury
Procedure: Remote Ischaemic Conditioning
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
|Official Title:||Effect of Remote Ischaemic Conditioning on Clinical Outcomes in ST-elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Multinational Multicentre Randomised Controlled Clinical Study|
- Cardiac mortality [ Time Frame: One year ]Cardiac mortality and hospitalisation for heart failure at one year
- Myocardial infarct size [ Time Frame: 72 hours ]Myocardial infarct size at day 3 (72 hours area under curve serum troponin T)
- Left ventricular function [ Time Frame: Three months ]Left ventricular function on day three and three months post pPCI (Echocardiography)
- Prognosis [ Time Frame: One year ]Re-infarction, stroke and revascularisation at one year
- Acute kidney injury [ Time Frame: 48-72 hours ]Changes in Serum Creatinine
|Study Start Date:||November 2013|
|Estimated Study Completion Date:||December 2017|
|Estimated Primary Completion Date:||July 2017 (Final data collection date for primary outcome measure)|
Experimental: Remote Ischaemic Conditioning
Use of Remote Ischaemic Conditioning prior to primary percutaneous coronary intervention
Procedure: Remote Ischaemic Conditioning
The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflate to 200 mmHg for 5 minutes followed by 5 minutes of deflations. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes).In recruiting centres where randomisation occurs at the hospital or in cases with short transportation time, the RIC protocol will continue during PCI until successful or until immediately before reperfusion.
No Intervention: No use of Remote Ischaemic Conditioning
No use of Remote Ischaemic Conditioning prior to percutaneous coronary intervention
Hide Detailed Description
Coronary heart disease (CHD) is the leading cause of death in Denmark and Europe, accounting for 1.92 million deaths in Europe per year: over one in five men (21%) and one in five women (22%) die from CHD.
Patients presenting with a ST-elevation Myocardial Infarction (STEMI)have despite advanced treatment with primary percutaneous coronary intervention (pPCI) a significant mortality and morbidity at one year with 17.4% of patients dying from a cardiovascular cause or being hospitalised from heart failure.
Remote Ischaemic Conditioning (RIC) applied at the time of myocardial reperfusion can reduce myocardial infarct size, confirming the existence of myocardial reperfusion injury. In this respect, RIC has been shown to limit myocardial infarct size and preserve cardiac function in STEMI patients undergoing pPCI.
RIC is performed in the ambulance during transport to the PCI unit by cycles of inflations of a blood pressure cuff to induce four 5-minute cycles of limb ischaemia and reperfusion. The method is virtually cost-free non-pharmacological and non-invasive therapeutic strategy.
RIC followed by pPCI improves clinical outcomes in STEMI patients when compared to STEMI controls undergoing standard pPCI evaluated one year post PCI.
Trial Design and aim:
Multinational investigator-driven, multi-centre, randomized, controlled, single-blind (Outcomes Assessor), parallel assignment, prospective clinical efficacy trial. A total of 4300 patients are to be included over a 36 months period.
Overall primary objective To determine whether RIC improves clinical outcomes (Cardiac mortality and hospitalisation for heart failure) at one year in 4300 STEMI patients undergoing pPCI.
To determine, in the pre-specified subgroups, whether age, gender, diabetes, and duration of chest pain to PCI influence the response to RIC.
To determine whether RIC preserves left ventricular function measured by echocardiography after three months post pPCI.
Study progress The patient will be informed and treated according to the national and international guidelines for Good Clinical Practice and protected under the Act concerning the processing of personal data and health law.
The admitting ambulance doctor or doctor at the receiving hospital will orally inform the patient and hand out the approved short written information. After information is given in the acute phase the patient does not have much time for reflection before signing the informed consent form.
Therefore a full written information and additional oral information will be given to the patient after the acute phase by a study nurse or the doctor performing the pPCI. As well during the first and second stage of information it will be emphasised that the patient has the right to withdraw his/her informed consent at any time.
After informed consent is obtained the patient will be randomised via a secure web-site to either pPCI with or without RIC by the the doctor on duty at the receiving hospitals. Computer-generated blocked randomisation lists, stratified by centre, will be prepared in advance of the study.
pPCI incl. the use of stents and antithrombotic regimens will be performed according to standard procedures at the treating hospital.
Blood samples (acute, 6-8, 24 and 48-72 hours after pPCI will be drawn during the acute phase at the treating hospital or at the local hospital.
Three days after pPCI an echocardiography (ECCO) will be performed at the hospital. Further three months after pPCI an ECCO will be performed at the hospital.
Information regarding re-hospitalisation or death will be drawn from electronic patient chart.
Benefit of the study Potential benefits: Participating patients will be offered an extra clinical out patient control, incl. an echocardiography three months after pPCI.
Disadvantage: In relation to the inflation of the blood pressure cuff temporary moderate pains in the treated arm might occur. Otherwise, the RIC has previously been proven to be without side effects.
An extra blood sampling of app. 15 ml will be drawn 48-72 hours after pPCI. A small but insignificant risk of local infection in relation to this is a risk.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01857414
|Contact: Hans Erik Bøtker, Professorfirstname.lastname@example.org|
|Contact: Kristine M Liendgaard, Adjunctemail@example.com|
|The Heart Centre, Aalborg Sygehus||Recruiting|
|Aalborg, Denmark, 9100|
|Contact: Søren Hjortshøj, Consultant firstname.lastname@example.org|
|Department of Cardiology, Aarhus University Hospital, Skejby||Recruiting|
|Aarhus, Denmark, 8200|
|Contact: Hans Erik Bøtker, Professor HEB@dadlnet.dk|
|Contact: Kristine M Liendgaard, Adjunct email@example.com|
|The Heart Centre, Rigshospitalet, Copenhagen University||Not yet recruiting|
|Copenhagen, Denmark, 2100|
|Contact: Thomas Engstrøm, Consultant Thomas.firstname.lastname@example.org|
|Department of Cardiology, Odense University Hospital||Recruiting|
|Odense, Denmark, 5000|
|Contact: Lissette O Jensen, Lecturer email@example.com|
|Military Medical Academy, Belgrade||Not yet recruiting|
|Belgrade, Serbia, 11000|
|Contact: Slobodan Obradovic, Professor firstname.lastname@example.org|
|The Clinical Center of Serbia||Not yet recruiting|
|Belgrade, Serbia, 11000|
|Contact: Dejan Milasinovic, Professor email@example.com|
|Contact: Goran Stankovic, Professor firstname.lastname@example.org|
|Hospital Universitario Central de Asturias||Recruiting|
|Oviedo, Spain, 33006|
|Contact: José MG Ruiz, Group leader email@example.com|
|The Hatter Cardiovascular Institute, University College London||Recruiting|
|London, United Kingdom, WC1E 6HX|
|Contact: Derek Hausenloy, Scientist firstname.lastname@example.org|
|Principal Investigator:||Hans Erik Bøtker, Professor||Aarhus University Hospital|